ClinicalTrials.gg
RecruitingNCT07099430Updated Oct 21, 2026

A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.

A Phase 1/2 interventional study of LBL-024 for Injection and Toripalimab Injection in Advanced Melanoma, sponsored by Nanjing Leads Biolabs Co.,Ltd. Recruiting at 16 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Nanjing Leads Biolabs Co.,Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Oct 21, 2026Site recruiting status changedEnrollment updated+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 203 studies in Melanoma with a site in China — 83 open to participants now, 95 under way, 5 of them phase 3. Melanoma · China.

Planned enrollment
16th of 189
280 · median 50
Started
2025
with 22 others
Phase 1/2
34 of 203
20 open now
Primary completion
2027-10
later than 56 of 94 live
Registered
167th of 203
by date

Among the 203 studies in Melanoma with a site in China, this one is the 16th largest by planned enrollment of the 189 interventional ones that give a count, is one of 23 that started in 2025, is one of 34 in phase 1/2, reaches primary completion later than 56 of the 94 other live ones, and was the 167th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

83 of the 203 studies in Melanoma with a site in China are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies in Melanoma with a site in China, or all of them as a file.
02

Study summary

This study is an open-label, multicenter phase Ib/II study to evaluate the efficacy and safety of LBL-024 monotherapy or combination with toripalimab in patients with advanced melanoma,To evaluate the preliminary efficacy and safety of LBL-024 monotherapy and combination therapy in patients with advanced melanoma.

Read the detailed description

This trial includes two phases, Phase Ib and Phase II.

Phase Ib is an exploratory stage of safety and efficacy in a single-arm, open-label study, including two cohorts (different dosing regimens).Phase Ib includes two cohorts, Cohort 1 (LBL-024 monotherapy) and Cohort 2 (LBL-024 + toripalimab combination).

Phase II includes Part A and Part B.Part A is a randomized, open-label, positive-controlled extension study. It plans to enroll patients with melanoma of the cutaneous, Acral, and unknown primary. Eligible subjects will be randomly assigned in a 2:1 ratio [Stratification factor: Acral subtype (Yes vs. No)] to either the Experimental Group or the Control Group. Part B is a single-arm extension study enrolling only patients with mucosal melanoma,and will select a drug combination based on phase Ib efficacy for expansion study.

This study requires subjects to provide relevant samples for testing. The trial will enroll up to 280 subjects.

03

Conditions studied

  • Advanced Melanoma

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Agree to follow the trial treatment regimen, visit schedule,laboratory test, and comply with other requirements of the protocol, and voluntarily enroll in the study and sign the written .
  2. At the time of signing the informed consent form, the age was ≥ 18 years old, and the gender was not limited.
  3. The 's physical status scoring standard (ECOG) is 0\~1.
  4. The expected survival time is at least 12 weeks.
  5. According to the evaluation of 1.1 (Response Evaluation Criteria in Solid Tumours), the subjects enrolled have at least one measurable neoplasm lesion.
  6. Male of and Females of childbearing age are willing to take highly effective measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who received within 4 weeks before the first dose or were planned to receive live vaccination during the study period and 4 weeks after the dose.
  2. Major surgery or other treatment or diagnosis that has a significant impact on the participant within 4 weeks before the first dose.
  3. Patients with active, or who have had and have the possibility of recurrence of diseases.
  4. History of severe cardiovascular and cerebrovascular disorder.
  5. Active infectious disease.
  6. History of mental illness (interfering with understanding or giving ), drug abuse, alcoholism, or drug addiction.
  7. Women during pregnancy or lactation.
  8. The investigator believes that the participant has other conditions that may affect compliance or are not suitable for participating in this study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    LBL-024

    LBL-024 monotherapy: Subjects received treatment with LBL-024 , intravenous infusion.

    Drug: LBL-024 for Injection

  • Experimental
    LBL-024 + toripalimab combination

    LBL-024 + toripalimab combination : Subjects received treatment with LBL-024 combined with toripalimab , both intravenous infusion.

    Drug: LBL-024 for Injection · Drug: Toripalimab Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Occurrence of adverse event (AE) and serious adverse event (SAE)

    Adverse event (AE) will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 5.0.The safety profile of LBL-024 monotherapy or combination therapy will be assessed by monitoring the adverse event (AE) and serious adverse event (SAE) in Phase Ib study.

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (90 days after drug withdrawal or before the start of new anti-tumor therapy)

  2. Objective Response Rate (ORR)

    According to the evaluation criteria of RECIST V1.1 (solid tumour) ,Proportion of subjects achieving complete response (CR) or partial response (PR).It was used to evaluate the efficacy in Phase Ib.

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

  3. Progression-free Survival(PFS)

    According to the evaluation criteria of RECIST V1.1 (solid tumour),Time from first dose to disease progression or death from any cause.It was used to evaluate Time of disease no-progression or Drug resistance in Phase II.

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

Secondary outcomes

  1. Cmax

    Maximum drug concentration in plasma after administration.

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

  2. Tmax

    After administration,Time to reach maximum drug concentration in plasma.

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

  3. Immunogenicity

    The immunogenicity is evaluated by the incidence of anti-drug antibodies (ADA) and neutralizing antibodies (if applicable) in subjects.Immunogenicity refers to the performance that can elicit an immune response.

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

  4. Disease Control Rate(DCR)

    Percentage of participants achieving CR, PR, iCR, iPR and stable disease (SD) after treatment.

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

  5. Duration of Response(DOR)

    DOR is defined as the duration from earliest date of disease response (CR、PR 、iCR or iPR) until earliest date of disease progression or death from any cause(if occurring sooner than progression).

    Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)

07

Study locations

10 of 16 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Oct 2027, 25 months after the start.

Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 84. This study's planned 25 months is below that.

Counting every sponsor, half of 220 studies reached it within 60 months; a quarter within 42 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2025
First posted
Aug 1, 2025
StartActual
Sep 5, 2025
Primary completionEst.
Oct 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. The First Hospital of Jilin University is now Recruiting
Show site
  • Beijing GoBroad Hospital · Beijing, China
Oct 21, 2026
Enrollment
200→280
Oct 21, 2026
Eligibility
2 exclusion criteria edited
What changed in the criteria
Exclusion criteria
  • EditedMajor surgery or other treatment or diagnosis that has a significant impact on the subjectparticipant within 4 weeks before the first dose.
  • EditedThe investigator believes that the subjectparticipant has other conditions that may affect compliance or are not suitable for participating in this study.
Oct 21, 2026
Interventions
Removed Drug: LBL-007 Injection. Arms removed: LBL-024 + LBL-007 combination
Oct 21, 2026
Title
A Trial of LBL-024 Monotherapy, LBL-024 Combined or Combination With LBL-007 or Toripalimab in Patients With Advanced Melanoma.
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    1 site added. The First Hospital of Jilin University is now Recruiting
    Show site
    • Beijing GoBroad Hospital · Beijing, China
    Enrollment 200→280
    Eligibility 2 exclusion criteria edited
    What changed in the criteria
    Exclusion criteria
    • EditedMajor surgery or other treatment or diagnosis that has a significant impact on the subjectparticipant within 4 weeks before the first dose.
    • EditedThe investigator believes that the subjectparticipant has other conditions that may affect compliance or are not suitable for participating in this study.
    Interventions Removed Drug: LBL-007 Injection. Arms removed: LBL-024 + LBL-007 combination
    Title A Trial of LBL-024 Monotherapy, LBL-024 Combined or Combination With LBL-007 or Toripalimab in Patients With Advanced Melanoma.
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07099430
Lead sponsor
Nanjing Leads Biolabs Co.,Ltd
Responsible party
Sponsor
First posted
Aug 1, 2025
Start date
Sep 5, 2025
Primary completion
Oct 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Yu Chen
Contact
maxy@leadsbiolabs.com
025-83378099
Yu Chen
principal investigator · Fujian Cancer Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-L1/4-1BB Bispecific Antibody LBL-024

Start the discussion